Using Stem Cells to Treat Dry AMD and Stargardt’s Macular Dystrophy
June 23, 2011
Advanced Cell Technology announced recently that it had enrolled the first patients in its two Phase I/II clinical trials, using retinal pigment epithelial (RPE) cells derived from embryonic stem cells (hESCs) for treating Stargardt’s Macular Dystrophy (SMD) and for the treatment of the dry form of age-related macular degeneration (Dry AMD). The first of twelve patients in each trial were enrolled at the Jules Stein Eye Institute at the University of California, Los Angeles (UCLA).
The two patients will be treated with immunosuppressants for about a week before the RPE cells will be implanted.
To read the full announcement, follow this link.
Jump down to form below to submit your own comments